NONOF Quote, Financials, Valuation and Earnings

Genmab A/S has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of 2.93%. Novo Nordisk A/S's return on equity of 62.44% beat Genmab A/S's return on equity of 17.69%.

Novo Nordisk A/S has a consensus price target of $53.99, signalling upside risk potential of 34.4%. On the other hand Genmab A/S has an analysts' consensus of $37.39 which suggests that it could grow by 27.74%. Given that Novo Nordisk A/S has higher upside potential than Genmab A/S, analysts believe Novo Nordisk A/S is more attractive than Genmab A/S.

Novo Nordisk A/S has a beta of 0.650, which suggesting that the stock is 35.045% less volatile than S&P 500. In comparison Genmab A/S has a beta of 0.899, suggesting its less volatile than the S&P 500 by 10.054%.

Novo Nordisk A/S has a quarterly dividend of $0.59 per share corresponding to a yield of 4.31%. Genmab A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 50.75% of its earnings as a dividend. Genmab A/S pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are larger than Genmab A/S quarterly revenues of $1.1B. Novo Nordisk A/S's net income of $4.2B is higher than Genmab A/S's net income of $31M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 11.58x while Genmab A/S's PE ratio is 18.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 3.82x versus 5.00x for Genmab A/S. Usually stocks with elevated PS ratios are considered overvalued.

Hims & Hers Health, Inc. has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of 2.63%. Novo Nordisk A/S's return on equity of 62.44% beat Hims & Hers Health, Inc.'s return on equity of 25.63%.

Novo Nordisk A/S has a consensus price target of $53.99, signalling upside risk potential of 34.4%. On the other hand Hims & Hers Health, Inc. has an analysts' consensus of $27.46 which suggests that it could grow by 77.04%. Given that Hims & Hers Health, Inc. has higher upside potential than Novo Nordisk A/S, analysts believe Hims & Hers Health, Inc. is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.650, which suggesting that the stock is 35.045% less volatile than S&P 500. In comparison Hims & Hers Health, Inc. has a beta of 2.431, suggesting its more volatile than the S&P 500 by 143.147%.

Novo Nordisk A/S has a quarterly dividend of $0.59 per share corresponding to a yield of 4.31%. Hims & Hers Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 50.75% of its earnings as a dividend. Hims & Hers Health, Inc. pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are larger than Hims & Hers Health, Inc. quarterly revenues of $599M. Novo Nordisk A/S's net income of $4.2B is higher than Hims & Hers Health, Inc.'s net income of $15.8M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 11.58x while Hims & Hers Health, Inc.'s PE ratio is 28.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 3.82x versus 1.74x for Hims & Hers Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of 34.4%. Novo Nordisk A/S's return on equity of 62.44% beat Eli Lilly & Co.'s return on equity of 104.39%.

Novo Nordisk A/S has a consensus price target of $53.99, signalling upside risk potential of 34.4%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,212.82 which suggests that it could grow by 14.57%. Given that Novo Nordisk A/S has higher upside potential than Eli Lilly & Co., analysts believe Novo Nordisk A/S is more attractive than Eli Lilly & Co..

Novo Nordisk A/S has a beta of 0.650, which suggesting that the stock is 35.045% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Novo Nordisk A/S has a quarterly dividend of $0.59 per share corresponding to a yield of 4.31%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.73 per share. Novo Nordisk A/S pays 50.75% of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Novo Nordisk A/S's net income of $4.2B is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Novo Nordisk A/S's price-to-earnings ratio is 11.58x while Eli Lilly & Co.'s PE ratio is 46.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 3.82x versus 14.80x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.